NAMS - NewAmsterdam Pharma Co N.V.

QQQ $ 454.82 $ 4.29 (0.95 %)

DIA $ 398.57 $ -0.02 (-0.01 %)

SPY $ 530.36 $ 3.48 (0.66 %)

TLT $ 91.26 $ 0.27 (0.3 %)

GLD $ 225.37 $ 0.20 (0.09 %)

Previous Close

$ 18.82

Open

$ 19.60

Bid

$ 18.79 x 100

Ask

$ 0.00 x 0

Day's Range

$ 18.69 - $ 19.76

52 Week Range

$ 5.63 - $ 26.35

Volume

131,706

Average Volume

Market Cap

1.69B

Beta (5Y Monthly)

$ 1.76

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
1	05-08-2024	03-31-2024	10-Q
2	02-28-2024	12-31-2023	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

NewAmsterdam Pharma Presents New Clinical ...
05/21/2024 12:25:41

-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact o...

TD Cowen Initiates Coverage On NewAmsterda...
05/15/2024 17:12:04

TD Cowen analyst Tyler Van Buren initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating.

NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0....
05/09/2024 13:04:29

First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $...

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
04/29/2024 20:31:14

Newamsterdam Pharma Enrolls Over 9,000 Pat...
04/09/2024 12:54:03

NewAmsterdam Pharma To Present New Analysi...
03/25/2024 12:21:22

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin me...

Scotiabank Initiates Coverage On NewAmster...
03/14/2024 11:40:42

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and...

Scotiabank Initiates Coverage On NewAmster...
03/13/2024 21:22:42

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and...

NewAmsterdam Pharma Announced Dosing Of Th...
03/12/2024 12:13:38

RBC Capital Maintains Outperform on NewAms...
02/29/2024 17:09:49

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and raises the price targe...

NewAmsterdam Pharma Reports Full Year 2023...
02/28/2024 13:14:02

Full Year 2023 Financial ResultsCash Position: As of December 31, 2023, NewAmsterdam recorded cash of $340.5 million, compared ...

NewAmsterdam Pharma Prices $175.3M Public ...
02/14/2024 07:40:15

NewAmsterdam Pharma announced the pricing of the previously announced underwritten public offering of (i) 4,488,159 of the Comp...

NewAmsterdam Pharma Reveals Commencement O...
02/13/2024 21:03:33

In addition, the Company expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exc...

why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session

Why TransCode Therapeutics Shares Are Trad...
01/19/2024 18:05:18

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

world-acceptance-posts-upbeat-earnings-joins-kaman-spirit-airlines-and-other-big-stocks-moving-higher-on-friday

World Acceptance Posts Upbeat Earnings, Jo...
01/19/2024 15:20:42

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporatio...

Guggenheim Initiates Coverage On NewAmster...
01/18/2024 12:11:09

Guggenheim analyst Debjit Chattopadhyay initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and announ...

Piper Sandler Initiates Coverage On NewAms...
01/16/2024 20:26:14

Piper Sandler analyst Yasmeen Rahimi initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Overweight rating and an...

cholesterol-player-newamsterdam-pharmas-obicetrapib-is-a-potential-blockbuster-in-cardiovascular-market-bullish-analyst-says

Cholesterol Player NewAmsterdam Pharma's O...
01/16/2024 19:48:08

Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor target...

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
01/15/2024 13:05:45

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
01/10/2024 21:31:09